Day One
Tuesday - October 31, 2023
Conference Day One
Tuesday 31st October 2023
7:15 am
Registration & Breakfast
8:10 am Chair’s Opening Remarks
8:30 am HER2-Directed Antibody Drug Conjugates in Breast Cancer: Recent Progress and Future Opportunities
Synopsis
For full session details, download the full event guide
9:00 am Industry Keynote: Next Steps for Enhertu to Reach More Patients with Unmet Needs Outside of Breast Cancer
Synopsis
For full session details, download the full event guide
9:30 am
Speed Networking & Morning Break
Maximizing HER2+ Primary Tumor Killing Through Various APIs, Methods of Drug Delivery & Immune System Engagement
10:30 am HER2 Gene Amplification & Overexpression in Non-Breast Carcinomas Compared to Breast Cancer
Synopsis
For full session details, download the full event guide
11:00 am Exploring Design Aspects for HER2-targeting ADCs
Synopsis
For full session details, download the full event guide
11:30 am Utilizing Molecular Engineering Methods to Maximize Adoptive Cell Therapy in HER2 Cancers
Synopsis
For full session details, download the full event guide
12:00 pm
Lunch Break
1:00 pm Development from Preclinical to Clinical: Strengths of Immunological Therapeutics vs. Targeted Chemotherapy
Synopsis
For full session details, download the full event guide
1:30 pm Taking a Genomic Approach to HER2 Drug Design: A Case Study With ARX788
Synopsis
For full session details, download the full event guide
Testing Next Generation Therapeutics & Combinations for Specific Non-Breast HER2 Expressing Gut, Bowel and Lung Tumors With Well-Designed Indication-Agnostic Trials
2:00 pm Utilizing High Power Beta Radiation to Induce Tumor Cell Death
Synopsis
For full session details, download the full event guide
2:30 pm Preclinical Antitumor Activity of a Multi-Modality Approach to Treating HER2 Tumors
Synopsis
For full session details, download the full event guide
3:00 pm
Afternoon Break – Poster Session
4:00 pm Panel Discussion: Putting the Pieces Together – Identifying the Characteristics that HER2 Therapeutics Need in Their Design to Enable Them to Achieve Efficacious Results in Breast & Non-Breast Tumors?
Synopsis
For full session details, download the full event guide
4:30 pm Treating HER2 Primary & Secondary Tumor Types Phase 1 Clinical Trial Results Overview
Synopsis
For full session details, download the full event guide
5:00 pm Chair’s Closing Remarks
5:15 pm End of Day One
Download the Full Event Guide for more information on:
- 20+ Expert Speaker Faculty
- Interactive workshops
- Full access to the 3-day conference agenda
- & more